Laura Airas
Professor of Neuroimmunology, MD, PhD
laura.airas@utu.fi Itäinen Pitkäkatu 4 Turku |
Neurology; Neuroimmunology; Multiple sclerosis; PET-imaging; MRI; Drug development
Multiple sclerosis research, @multiplesclerosisresearchfinland, Neuroinflammation research, INFLAMES Flagship
Laura Airas is an internationally recognized expert in multiple sclerosis (MS) and has served as Professor of Neuroimmunology at the University of Turku since 2017. She also practices clinically as a neurologist at Turku University Hospital, specializing in the care of MS patients.
Professor Airas earned her MD from the University of Turku in 1991 and completed her PhD in immunology and cell biology under Professor Sirpa Jalkanen. Her dissertation was recognized with a special distinction from the University of Turku. She became a specialist in neurology in 2001 and was appointed Associate Professor (docent) in 2007.
Her international experience includes serving as a Visiting Professor at Yale University in 2016–2017. In 2015, she was awarded the prestigious Grant for Multiple Sclerosis Innovation (GMSI).
Professor Airas is a respected member of the international scientific community. She serves as a reviewer for major neurology and neuroimmunology journals and funding agencies, and is a frequent invited speaker at national and international scientific events.
Professor Airas leads a translational and patient-centered research group focusing on the pathophysiology of progressive MS and the development of novel therapeutic strategies. Her research integrates cutting-edge imaging techniques (PET and MRI), biomarker discovery, and genetic analysis to investigate the role of glial cells in brain neurodegeneration.
Her multidisciplinary group of about 20 members includes physicians, biomedical scientists, biosiatisticians, and students. They collaborate widely with national and international partners in PET imaging, immunology, drug development, and neuroscience.
The research is funded by:
- Research Council of Finland
- State Research Funding (VTR)
- Jane and Aatos Erkko Foundation
- U.S.-based organizations including the U.S. Department of Defense, National MS Society, and the Progressive MS Alliance
The group is a member of the InFLAMES Flagship at the University of Turku, where Professor Airas also serves on the leadership team.
In addition to her academic work, Professor Airas has been the Principal Investigator in numerous international multicenter clinical trials. She currently leads two investigator-initiated trials targeting microglial activation to slow down progression of MS.
Professor Laura Airas is actively engaged in teaching at the University of Turku. She lectures in neurology and neuroimmunology for students in the medical and biomedical degree programmes and trains specialist physicians in neurology.
Her teaching approach emphasizes patient-centeredness, integration of clinical care and research, and the application of up-to-date scientific knowledge. She brings insights from the latest breakthroughs in neuroimmunology and clinical trial methodology directly into the classroom.
Professor Airas also supervises PhD candidates and has served as the primary supervisor for several completed doctoral theses. In addition, she contributes to postgraduate education programmes for neurology specialists and neuroscience professionals. She is a sought-after lecturer at both national and international medical education events.
- (2022)
- Therapeutic Advances in Neurological DisordersNeurology, Neuroimmunology and NeuroinflammationFrontiers in Neurology
- The White Matter Rounds experience: The importance of a multidisciplinary network to accelerate the diagnostic process for adult patients with rare white matter disorders (2022)
- Frontiers in Neurology
- Toward Precision Phenotyping of Multiple Sclerosis (2022)
- Neurology, Neuroimmunology and NeuroinflammationMultiple Sclerosis and Related Disorders
- (2022)
- Frontiers in immunologyMovement Disorders
- Akuutti transversaalimyeliitti vaatii nopean hoidon (2021)
- Duodecim
- Effect of dopaminergic medication on adenosine 2A receptor availability in patients with Parkinson's disease (2021)
- Parkinsonism and Related DisordersClinical Infectious Diseases
- Efficacy and tolerability of folate-aminopterin therapy in a rat focal model of multiple sclerosis (2021)
- Journal of Neuroinflammation
- Fingolimod treatment reverses signs of diffuse white matter damage in multiple sclerosis: A pilot study (2021)
- (2021)
- Increased serum glial fibrillary acidic protein associates with microstructural white matter damage in multiple sclerosis: GFAP and DTI (2021)
- Multiple Sclerosis and Related Disorders
- MS-tauti (2021) Kliininen neuropsykiatria Hämäläinen Päivi, Smith Emma, Airas Laura
- (2021)
- DuodecimJournal of Magnetic Resonance Imaging
- Oral Doxycycline Compared to Intravenous Ceftriaxone in the Treatment of Lyme Neuroborreliosis: A Multicenter, Equivalence, Randomized, Open-label Trial (2021)
- Positron emission tomography in multiple sclerosis - straight to the target (2021)
- Nature Reviews Neurology
- Pregnancy-Induced Changes in microRNA Expression in Multiple Sclerosis (2021)
- Frontiers in immunology
- Synaptic Loss in Multiple Sclerosis: A Systematic Review of Human Post-mortem Studies (2021)
- Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement (2021)
- Journal of Neuroimmunology
- Whole Brain Adiabatic T-1rho and Relaxation Along a Fictitious Field Imaging in Healthy Volunteers and Patients With Multiple Sclerosis: Initial Findings (2021)
- Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis (2020)
- Brain
- Decreased Availability of Adenosine 2A Receptors in the Caudate in Patients with Early Stage Parkinson’s Disease (2020)